QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.103.054569v1 307/3/831    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Anantharam, A. Articles by Abbott, G. W. Search for Related Content PubMed PubMed Citation Articles by Anantharam, A. Articles by Abbott, G. W.

PERSPECTIVES IN PHARMACOLOGY

Pharmacogenetic Considerations in Diseases of Cardiac Ion Channels

Division of Cardiology, Department of Medicine (A.A., S.M.M., G.W.A.); Graduate Program in Neuroscience (A.A.); Department of Pharmacology (G.W.A.); Weill Medical College of Cornell University, New York, New York

Phenotypic variation within a species arises from differences in genetic makeup between individuals. This inherent diversity empowers the species as a whole to explore and expand into new environmental niches and also to survive new stressors within an ever-changing environment. Paradoxically, one class of stressors currently challenging the human population is therapeutic drugs: medications designed to combat disease are often associated with a host of nonspecific side effects. Following earlier studies of the involvement of some cardiac ion currents in unwanted drug interactions, recent reports have identified not only the ion channel subunits involved but also a range of mutations and single nucleotide polymorphisms in ion channel genes that predispose to both drug-induced and familial cardiac arrhythmia. The tendency for individuals harboring specific, often common, gene variants to succumb to life-threatening cardiac arrhythmia, and the contribution of other factors such as drug interaction to disease etiology in these cases, are discussed here together with potential pharmacogenetic strategies for arrhythmia circumvention and therapy.

Address correspondence to: Dr. Geoffrey W. Abbott, Division of Cardiology, Dept. of Medicine, Weill Medical College of Cornell University, Starr 463, 520 East 70th Street, New York, NY 10021. E-mail: gwa2001{at}med.cornell.edu

This article has been cited by other articles:

				T. K. Roepke, A. Kontogeorgis, C. Ovanez, X. Xu, J. B. Young, K. Purtell, P. A. Goldstein, D. J. Christini, N. S. Peters, F. G. Akar, et al. Targeted deletion of kcne2 impairs ventricular repolarization via disruption of IK,slow1 and Ito,f FASEB J, October 1, 2008; 22(10): 3648 - 3660. [Abstract] [Full Text] [PDF]

				D. A. Drubin, J. C. Way, and P. A. Silver Designing biological systems Genes & Dev., February 1, 2007; 21(3): 242 - 254. [Abstract] [Full Text] [PDF]

				E. Schulze-Bahr Arrhythmia Predisposition: Between Rare Disease Paradigms and Common Ion Channel Gene Variants J. Am. Coll. Cardiol., October 27, 2006; 48(9_Suppl_A): A67 - A78. [Abstract] [Full Text] [PDF]

				K. M. Hurley, S. Gaboyard, M. Zhong, S. D. Price, J. R. A. Wooltorton, A. Lysakowski, and R. A. Eatock M-Like K+ Currents in Type I Hair Cells and Calyx Afferent Endings of the Developing Rat Utricle J. Neurosci., October 4, 2006; 26(40): 10253 - 10269. [Abstract] [Full Text] [PDF]

				R. Roberts Genomics and Cardiac Arrhythmias J. Am. Coll. Cardiol., January 3, 2006; 47(1): 9 - 21. [Abstract] [Full Text] [PDF]

				F. Mari, E. Bertol, V. Fineschi, and S. B Karch Channelling the Emperor: what really killed Napoleon? J R Soc Med, August 1, 2004; 97(8): 397 - 399. [Abstract] [Full Text] [PDF]